Publications

5600 Results

SWOG S2012: Randomized Phase II/III Trial of First Line Platinum (P) / Etoposide (E) with or without Atezolizumab (NSC #783608) in Patients with Advanced or Metastatic Poorly Differentiated Extrapulmonary Neuroendocrine Carcinomas (NEC)

Authors
D Zhen;A Moseley;EG Chiorean;E Burgess;E Swisher;C Gay;L Byers;I Wistuba;H Mahdi;J Starr;M Othus;Y Chae;R Kurzrock
Journal / Conference
ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), TIPS, poster; J Clin Oncol 42, 2024 (suppl 16; abstr TPS4201)
Year
2024
Research Committee(s)
Early Therapeutics and Rare Cancers
Study Number(s)
S2012

A phase III randomized trial of eribulin (E) with gemcitabine vs standard of care (SOC) for metastatic urothelial carcinoma (UC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937- Updated Design

Authors
S Sadeghi;M Plets;P Lara;C Tangen;S Berg;J Brown;R Bangs;D Nakagawa;S Daneshmand;I Thompson;T Flaig;D Petrylak;S Lerner
Journal / Conference
ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), poster; J Clin Oncol 42, 2024 (suppl 16; abstr TPS4617)
Year
2024
Research Committee(s)
Genitourinary
Study Number(s)
S1937

Association between Postoperative Circulating Tumor DNA (ctDNA) and Recurrence-Free Survival (RFS) in Patients with Resected Stage III Melanoma - an Exploratory Analysis of SWOG S1404

Authors
M LaPelusa;D Marcano;M Othus;A Grossmann;V Aushev;B Sridhar;D Renner;H Sethi;M Liu;A Tarhini;J Kirkwood;K Grossmann;J Moon;H Li;S Mashrun;N Khushalani;E Sharon;L Korde;A Ribas;S Patel
Journal / Conference
ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), poster; J Clin Oncol 42, 2024 (suppl 16; abstr 9564)
Year
2024
Research Committee(s)
Melanoma
Study Number(s)
S1404

Treatment discontinuation due to toxicity for patients with acute myeloid leukemia (AML) treated on SWOG S1203

Authors
S Raychaudhuri;M Othus;M Percival;G Garcia-Manero;F Appelbaum;H Erba;J Appelbaum
Journal / Conference
ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), poster;J Clin Oncol 42, 2024 (suppl 16; abstr 6529)
Year
2024
Research Committee(s)
Leukemia
Study Number(s)
S1203

Lung-MAP S1800D: A Phase II/III Study of N-803 (ALT-803) plus Pembrolizumab versus Standard of Care in Participants with Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) Previously Treated with Anti-PD-1 or Anti-PD-L1 Therapy

Authors
J Wrangle;M Redman;H Husain;K Reckamp;T Stinchcombe;M Edelman;T Leal;B Faller;K Minichiello;H Borghaei;K Kelly;RS Herbst;JE Gray
Journal / Conference
ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), poster;J Clin Oncol 42, 2024 (suppl 16; abstr 2619)
Year
2024
Research Committee(s)
Lung
Study Number(s)
S1800D

Risk Prediction Model for Taxane-Induced Peripheral Neuropathy in Patients with Early-Stage Cancer Receiving Taxane Therapy: SWOG S1714 (NCT# 03939481)

Authors
M Trivedi;J Unger;D Hershman;A Darke;D Hertz;T Brannagan;S Smith;B Schneider;W Irvin;A Hathaway;A Vander Woude;V Gudena;P Cabrera-Galean;M Orsted;M LeBlanc;NL Henry;MJ Fisch
Journal / Conference
ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), oral; J Clin Oncol 42, 2024 (suppl 16; abstr 12005)
Year
2024
Research Committee(s)
Symptom Management and Survivorship
Study Number(s)
S1714

Correlation of serum anti-Müllerian hormone (AMH) levels on identification of premenopausal patients (pts) with hormone receptor positive (HR+), HER2-negative, node-positive breast cancer most likely to benefit from adjuvant chemotherapy in SWOG S1007 (RxPONDER)

Authors
K Kalinsky;W Barlow;H Pathak;J Gralow;K Albain;D Hayes;N Lin;E Perez;L Goldstein;S Chia;P Rastogi;A Schott;S Shak;D Tripathy;G Hortobagyi;F Meric-Bernstam;P Sharma;L Pusztai;A Thompson;A Godwin
Journal / Conference
ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), oral presentation; J Clin Oncol 42, 2024 (suppl 16; abstr 505)
Year
2024
Research Committee(s)
Breast
Study Number(s)
S1007

Evaluation of mixed response in tumor size and survival in patients with rare cancers treated with dual checkpoint inhibitor therapy (DART SWOG S1609)

Authors
Y Chae;E Dietrich;M Othus;L Il-Young Chung;H Kim;C Ryan;CD Blanke;S Patel;R Kurzrock
Journal / Conference
ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), Rapid Oral Abstract Session; J Clin Oncol 42, 2024 (suppl 16; abstr 2514)
Year
2024
Research Committee(s)
Early Therapeutics and Rare Cancers
Study Number(s)
S1609

SWOG S2107 - Randomized Phase II Trial of Encorafenib and Cetuximab with or Without Nivolumab for Patients with Previously Treated, Microsatellite Stable, BRAFV600E Metastatic and/or Unresectable Colorectal Cancer

Authors
VK Morris;KA Guthrie;ES Kopetz;R Breakstone;T Karasic;I Hu;S Colby;M Fakih;S Gholami;PJ Gold;EG Chiorean;PA Philip
Journal / Conference
ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), TIPS, poster; J Clin Oncol 42, 2024 (suppl 16; abstr TPS3640)
Year
2024
Research Committee(s)
Gastrointestinal
Study Number(s)
S2107

Plant-Based Diet and Survival Among Patients with Metastatic Colorectal Cancer: Findings from the CALGB/SWOG 80405 (Alliance)

Authors
E Cheng;F Ou;C Ma;A Venook;H-J Lenz;E O'Reilly;P Campbell;C Kuang;B Caan;K Ng;J Meyerhardt
Journal / Conference
AACR Annual Meeting (April 5-10, 2024, San Diego, CA), poster
Year
2024
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/C80405